

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 4 of Short Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.11377 – ARDIAN / DEDALUS HEALTHCARE SYSTEMS

SECTION 4

Description of the concentration

This notification concerns the following undertakings:

- Ardian France S.A. (Ardian, France)
- Dedalus Healthcare Systems Group S.p.A. (DHSB, Italy, currently jointly controlled by HealthLux S.A. and Health Holding Company S.r.l.). DHSB is the holding company which holds, indirectly through Dedalus Holding 2 S.p.A. ("Dedalus Holding 2"), the entire share capital of Dedalus S.p.A. ("**Dedalus**" together with its subsidiaries, the "**Dedalus Group**")

HealthLux – currently exercising joint control over DHSB together with Health Holding Company S.r.l. (HHC) because of HHC veto rights for the approval of budget, business plan and investments provided for in DHSB By-Laws - acquires, within the meaning of Article 3(1), point (b) of the EUMR, sole control of DHSB. As a result, Ardian, ultimately controlling HealthLux, will acquire indirect sole control over DHSB.

The concentration is accomplished by way of purchase of shares and amendments to the By-Laws of DHSB. For completeness, the same amendments to DHSB By-Laws will also be reflected in the by-laws of some companies of the Dedalus Group (among which Dedalus Holding 2 and Dedalus).

The business activities of the undertakings concerned are:

- a. for Ardian: private equity business engaged in the provision of investment management services to a number of investment funds.
- b. for Dedalus: production and sale of software for the healthcare, medical, diagnostic and pharmaceutical market.